Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 977-990 |
| Number of pages | 14 |
| Journal | Stem Cell Reports |
| Volume | 8 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 2017 |
Fingerprint
Cite this
Efficient Ex Vivo Engineering and Expansion of Highly Purified Human Hematopoietic Stem and Progenitor Cell Populations for Gene Therapy. / Zonari, E; Desantis, G; Petrillo, Carolina; Boccalatte, FE; Lidonnici, MR; Kajaste-Rudnitski, A; Aiuti, A; Ferrari, G; Naldini, L; Gentner, B.
In: Stem Cell Reports, Vol. 8, No. 4, 2017, p. 977-990.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Efficient Ex Vivo Engineering and Expansion of Highly Purified Human Hematopoietic Stem and Progenitor Cell Populations for Gene Therapy
AU - Zonari, E
AU - Desantis, G
AU - Petrillo, Carolina
AU - Boccalatte, FE
AU - Lidonnici, MR
AU - Kajaste-Rudnitski, A
AU - Aiuti, A
AU - Ferrari, G
AU - Naldini, L
AU - Gentner, B
PY - 2017
Y1 - 2017
N2 - Ex vivo gene therapy based on CD34+ hematopoietic stem cells (HSCs) has shown promising results in clinical trials, but genetic engineering to high levels and in large scale remains challenging. We devised a sorting strategy that captures more than 90% of HSC activity in less than 10% of mobilized peripheral blood (mPB) CD34+ cells, and modeled a transplantation protocol based on highly purified, genetically engineered HSCs co-infused with uncultured progenitor cells. Prostaglandin E2 stimulation allowed near-complete transduction of HSCs with lentiviral vectors during a culture time of less than 38 hr, mitigating the negative impact of standard culture on progenitor cell function. Exploiting the pyrimidoindole derivative UM171, we show that transduced mPB CD34+CD38− cells with repopulating potential could be expanded ex vivo. Implementing these findings in clinical gene therapy protocols will improve the efficacy, safety, and sustainability of gene therapy and generate new opportunities in the field of gene editing. © 2017 The Author(s)
AB - Ex vivo gene therapy based on CD34+ hematopoietic stem cells (HSCs) has shown promising results in clinical trials, but genetic engineering to high levels and in large scale remains challenging. We devised a sorting strategy that captures more than 90% of HSC activity in less than 10% of mobilized peripheral blood (mPB) CD34+ cells, and modeled a transplantation protocol based on highly purified, genetically engineered HSCs co-infused with uncultured progenitor cells. Prostaglandin E2 stimulation allowed near-complete transduction of HSCs with lentiviral vectors during a culture time of less than 38 hr, mitigating the negative impact of standard culture on progenitor cell function. Exploiting the pyrimidoindole derivative UM171, we show that transduced mPB CD34+CD38− cells with repopulating potential could be expanded ex vivo. Implementing these findings in clinical gene therapy protocols will improve the efficacy, safety, and sustainability of gene therapy and generate new opportunities in the field of gene editing. © 2017 The Author(s)
U2 - 10.1016/j.stemcr.2017.02.010
DO - 10.1016/j.stemcr.2017.02.010
M3 - Article
VL - 8
SP - 977
EP - 990
JO - Stem Cell Reports
JF - Stem Cell Reports
SN - 2213-6711
IS - 4
ER -